Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

T-cell depletion by alefacept reported effective in psoriatic lesions

Dec. 2, 2002

GAM product evaluated in phase I trial for diabetic foot ulcers

Nov. 29, 2002

PCL-016 enters phase IIa in acne

Nov. 28, 2002

SRP-299 enters phase II in childhood atopic dermatitis

Nov. 27, 2002

RegeneRx files IND for thymosin beta 4

Nov. 20, 2002

U. of British Columbia and ARC sign license agreement for novel antiinflammatories

Nov. 19, 2002

Recombinant alpha 1-antitrypsin topical gel enters clinical trials

Nov. 14, 2002

Update of PVAC treatment program for psoriasis

Nov. 13, 2002

Enrollment begins in pivotal phase III trials of Atrisone for acne

Nov. 8, 2002

Approvable letter for Olux expanded label

Oct. 31, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...